ATE429245T1 - Durch mycobacterium tuberculosis und nicht durch bcg exprimierte proteine und ihre verwendung als diagnostische reagenzien und impfstoffe - Google Patents

Durch mycobacterium tuberculosis und nicht durch bcg exprimierte proteine und ihre verwendung als diagnostische reagenzien und impfstoffe

Info

Publication number
ATE429245T1
ATE429245T1 AT00928851T AT00928851T ATE429245T1 AT E429245 T1 ATE429245 T1 AT E429245T1 AT 00928851 T AT00928851 T AT 00928851T AT 00928851 T AT00928851 T AT 00928851T AT E429245 T1 ATE429245 T1 AT E429245T1
Authority
AT
Austria
Prior art keywords
bcg
mycobacterium tuberculosis
vaccines
proteins expressed
diagnostic reagents
Prior art date
Application number
AT00928851T
Other languages
English (en)
Inventor
Maria Gennaro
Original Assignee
Univ New Jersey Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22454351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE429245(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ New Jersey Med filed Critical Univ New Jersey Med
Application granted granted Critical
Publication of ATE429245T1 publication Critical patent/ATE429245T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0006—Skin tests, e.g. intradermal testing, test strips, delayed hypersensitivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/35—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/863—Mycobacterium

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Physiology (AREA)
AT00928851T 1999-05-04 2000-05-04 Durch mycobacterium tuberculosis und nicht durch bcg exprimierte proteine und ihre verwendung als diagnostische reagenzien und impfstoffe ATE429245T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13250599P 1999-05-04 1999-05-04
PCT/US2000/012257 WO2000066157A1 (en) 1999-05-04 2000-05-04 Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as diagnostic reagents and vaccines

Publications (1)

Publication Number Publication Date
ATE429245T1 true ATE429245T1 (de) 2009-05-15

Family

ID=22454351

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00928851T ATE429245T1 (de) 1999-05-04 2000-05-04 Durch mycobacterium tuberculosis und nicht durch bcg exprimierte proteine und ihre verwendung als diagnostische reagenzien und impfstoffe

Country Status (10)

Country Link
US (12) US7932373B1 (de)
EP (2) EP2087906A1 (de)
JP (1) JP4820489B2 (de)
AT (1) ATE429245T1 (de)
AU (1) AU773268B2 (de)
CA (1) CA2372583C (de)
DE (1) DE60042078D1 (de)
DK (1) DK1214088T3 (de)
ES (1) ES2326257T3 (de)
WO (1) WO2000066157A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2087906A1 (de) 1999-05-04 2009-08-12 The University of Medicine and Dentistry of New Jersey Durch Mycobacterium tuberculosis und nicht durch BCG exprimierte Proteine und deren Verwendung als diagnostische Reagenzien und Impfstoffe
AU2001250294A1 (en) * 2000-04-19 2001-10-30 Statens Serum Institut Tuberculosis antigens and methods of use thereof
ATE535600T1 (de) * 2002-04-05 2011-12-15 Pasteur Institut Identifizierung der virulenz-assoziierten region rd1, die die entwicklung von verbesserten impstoffen mit m. microti ermöglicht
WO2003093307A2 (en) * 2002-04-27 2003-11-13 The Secretary Of State For Environment, Food And Rural Affairs Mycobacterial antigens and uses thereof
GB0229444D0 (en) * 2002-12-18 2003-01-22 Royal Free Hampstead Nhs Trust Diagnostic method and assay kit
CA2616766A1 (en) 2005-07-26 2007-02-01 University Of Medicine And Dentistry Of New Jersey Antibody profiles characteristic of tuberculosis state
US8465753B2 (en) * 2007-04-23 2013-06-18 Robert J. Greenstein Combination vaccines against Mycobacterium sp. and methods of using the same
EP2441469A1 (de) * 2006-03-14 2012-04-18 Oregon Health and Science University Verfahren zur Erzeugung einer Immunantwort auf Tuberculosis
GB0618127D0 (en) * 2006-09-14 2006-10-25 Isis Innovation Biomarker
US9297803B2 (en) 2006-11-01 2016-03-29 Immport Therapeutics, Inc. Compositions and methods for immunodominant antigens
ES2335177B1 (es) * 2008-09-19 2011-02-28 Archivel Farma, S.L. Agente inmunoterapeutico apropiado para la profilaxis primaria de la tuberculosis.
EP2812704A4 (de) 2012-02-07 2016-03-23 Intuitive Biosciences Inc Mycobakteriumstuberkulose-spezifische peptide zur erkennung einer infektion oder immunisierung nichtmenschlicher primaten
CN104628834B (zh) * 2015-01-23 2016-03-23 中国疾病预防控制中心传染病预防控制所 一种结核感染t细胞免疫检测抗原及其应用
US10684275B2 (en) 2016-12-14 2020-06-16 Becton, Dickinson And Company Methods and compositions for obtaining a tuberculosis assessment in a subject

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977263A (en) 1992-12-10 1999-11-02 3M Innovative Properties Company Thermal transfer compositions, articles and graphic articles made with same
CA2230927A1 (en) 1995-09-01 1997-03-13 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
AU727602B2 (en) * 1995-09-01 2000-12-14 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6290969B1 (en) 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
ES2152419T3 (es) 1995-09-08 2001-02-01 Textilma Ag Telar.
BR9712298A (pt) 1996-10-11 2000-10-24 Corixa Corp Polipeptìdeo, molécula de dna, vetor de expressão recombinante, célula hospedeira, processo para detectar infecção por m. tuberculosis em uma amostra biológica, kit diagnóstico, anticorpos monoclonal, e, policlonal, e, proteìna de fusão
ATE370236T1 (de) * 1997-04-02 2007-09-15 Statens Seruminstitut Nukleinsäure- und polypeptidfragmente von m. tuberculosis
EP1003870A1 (de) 1997-07-16 2000-05-31 Institut Pasteur Polynukleotid, das für das lhp protein aus mycobacterium tuberculosis kodiert, dessen biologisch aktive fragmente, und verfahren zu deren verwendung
US6291190B1 (en) 1998-08-25 2001-09-18 The Board Of Trustees Of The Leland Stanford Junior University Molecular differences between species of the M. tuberculosis complex
EP2087906A1 (de) 1999-05-04 2009-08-12 The University of Medicine and Dentistry of New Jersey Durch Mycobacterium tuberculosis und nicht durch BCG exprimierte Proteine und deren Verwendung als diagnostische Reagenzien und Impfstoffe
AU2001250294A1 (en) 2000-04-19 2001-10-30 Statens Serum Institut Tuberculosis antigens and methods of use thereof
WO2003093307A2 (en) 2002-04-27 2003-11-13 The Secretary Of State For Environment, Food And Rural Affairs Mycobacterial antigens and uses thereof
US20070024122A1 (en) * 2005-07-27 2007-02-01 Steve Belson System and method for a distributed front end rectifier power system

Also Published As

Publication number Publication date
US8021832B2 (en) 2011-09-20
US20100016415A1 (en) 2010-01-21
CA2372583A1 (en) 2000-11-09
US20140220600A1 (en) 2014-08-07
US8992942B2 (en) 2015-03-31
US8974800B2 (en) 2015-03-10
US20160153986A1 (en) 2016-06-02
US8623609B2 (en) 2014-01-07
US20070224123A1 (en) 2007-09-27
US20170043038A1 (en) 2017-02-16
EP2087906A1 (de) 2009-08-12
US7579141B2 (en) 2009-08-25
JP2003519467A (ja) 2003-06-24
US9238066B2 (en) 2016-01-19
EP1214088A4 (de) 2003-06-11
JP4820489B2 (ja) 2011-11-24
US9844604B2 (en) 2017-12-19
EP1214088A1 (de) 2002-06-19
US7709211B2 (en) 2010-05-04
AU773268C (en) 2000-11-17
ES2326257T3 (es) 2009-10-06
US20130251739A1 (en) 2013-09-26
US20070224122A1 (en) 2007-09-27
DE60042078D1 (de) 2009-06-04
EP1214088B1 (de) 2009-04-22
US20110052637A1 (en) 2011-03-03
US20160169888A1 (en) 2016-06-16
US20120107247A1 (en) 2012-05-03
US9782495B2 (en) 2017-10-10
US20130149719A1 (en) 2013-06-13
CA2372583C (en) 2012-07-10
US7932373B1 (en) 2011-04-26
US9482671B2 (en) 2016-11-01
AU4702300A (en) 2000-11-17
WO2000066157A1 (en) 2000-11-09
AU773268B2 (en) 2004-05-20
DK1214088T3 (da) 2009-08-24

Similar Documents

Publication Publication Date Title
ATE429245T1 (de) Durch mycobacterium tuberculosis und nicht durch bcg exprimierte proteine und ihre verwendung als diagnostische reagenzien und impfstoffe
DE69937419D1 (de) Neisseria Meningitidis Antigene und Zusammenstellungen
WO2000066067A3 (en) Ibd-associated microbial antigens and methods of using same
WO2002032925A3 (en) Protein scaffolds for antibody mimics and other binding proteins
AU3948801A (en) Heterologous expression of neisserial proteins
ATE293159T1 (de) Stabilisierendes verdünnungsmittel für polypeptide und antigene
DE60124899D1 (de) Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
SG158141A1 (en) Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
DE60042066D1 (de) Chimärische dr4 antikörper und ihre verwendung
DE60042430D1 (de) An menschlichen Faktor-VIII bindende Moleküle und Faktor-VIII-ähnliche Proteine
ATE277171T1 (de) Ikk-alpha proteine, nukleinsäuren und verfahren
EP1109454A4 (de) Neisseria meningitidis-polypeptid, nukleinsäuresequenz und verwendungen davon
TR200003467T2 (tr) Neisseria meningitidis antijenik polipeptidler, mütekabil polinükleotidler ve koruyucu antikorlar
Lacayo William Levitt.
WO2000066143A8 (en) Secreted proteins of mycobacterium tuberculosis and their use as vaccines and diagnostic reagents
DE69935323D1 (de) Moraxella catharralis proteine
DE60120357D1 (de) Haemophilus influenza äusseres membranprotein und verwendung davon als impstoff
FR2826392B1 (fr) Dispositif d'assemblage des bords de panneaux, lattes ou lambris
WO2001092305A3 (en) Mammalian transforming growth factor beta-10
Jaidka Device for controlling air pollution
HU9902267D0 (en) Mv tamara variety of wheat (triticum aestivum l.)
DE60238243D1 (de) Polypeptide, abgeleitet von der amyloid vorläuferprotein (app), und ihre verwendungen
DE60139889D1 (de) Mutierte bcl-2 proteine und verwendung davon
ITRM20010257A0 (it) Procedimento per la rinaturazione, idrolisi e produzione di proteine pr ricombinanti, composizioni e kit utilizzabili in tali procedimenti.
EP1254256A4 (de) Neuartige nukleinsäure und polypeptide

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1214088

Country of ref document: EP